Dopaminergic dysbalance in distinct basal ganglia neurocircuits: Implications for the pathophysiology of parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder C. Mehler-WexP. RiedererM. Gerlach OriginalPaper Pages: 167 - 179
Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil Moussa B. H. YoudimTamar AmitMara Yogev-Falach OriginalPaper Pages: 181 - 192
Common efficacy of psychotropic drugs in restoring stress-induced impairment of prefrontal plasticity Nathalie DupinFranÇois MaillietTherese M. Jay OriginalPaper Pages: 193 - 198
Dopamine and incentive learning: A framework for considering antipsychotic medication effects Richard J. Beninger OriginalPaper Pages: 199 - 209
The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps? Mark A. Geyer OriginalPaper Pages: 211 - 220
Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms Joseph T. Coyle OriginalPaper Pages: 221 - 233
The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia John H. KrystalD. Cyril D’SouzaGodfrey Pearlson OriginalPaper Pages: 235 - 252
Importance of clinical diagnoses for comorbidity studies in substance use disorders Marta TorrensRocío Martin-SantosSharon Samet OriginalPaper Pages: 253 - 261
Neurotoxins and neurotoxicity mechanisms. an overview Juan Segura-AguilarRichard M. Kostrzewa OriginalPaper Pages: 263 - 285